| A mathematical/statistical model to describe the disposition of olaratumab was developed using data from four clinical studies. |
| The model describes the time course of olaratumab disposition in the body of all patients included in the analysis and predicts disposition in additional patient populations. |
| The described model is the most comprehensive understanding of the pharmacokinetic properties of olaratumab. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.